SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.
Hepatocellular Carcinoma
DRUG: Selinexor Pill|DRUG: Bevacizumab|DRUG: Atezolizumab
Maximum Tolerated Dose, Maximum Tolerated Dose (MTD) of Selinexor when combined with Bevacizumab and Atezolizumab will be determined by testing 2 dose levels. MTD reflects that highest dose that did not cause Dose Limiting Toxicity (DLT), Up to 24 months
Rate of Objective Response (per RECIST), Objective response is defined as the sum of complete and partial response as determined by Response Evaluation in Solid Tumors (RECIST) guidelines version 1.1, Up to 24 months|Rate of Objective Response (per mRECIST), Objective response is defined as the sum of complete and partial response as determined by hepatocellular carcinoma modified RECIST (mRECIST)., Up to 24 months|Progression Free Survival, Progression Free Survival (PFS) defined as the time from start of treatment to documented disease progression or death due to any cause., Up to 24 months|Overall Survival, Overall Survival (OS) defined as the time from first dose of study treatment until death from any cause., up to 24 months
The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.